IDH1 and neoplasm: Heidenreich and colleagues [31] have also shown that for primary GBMs, there is an inverse correlation between mutations in the therapeutic/diagnostic markers of isocitrate dehydrogenase 1 (IDH1) and alterations in the above promoter coordinates of TERT. Since all of our tumor samples are IDH1wt, observation of the above TERT promoter mutations in 76% of the patients is consistent with previous results.